| Date | Title | Description |
| 27.08.2026 | Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ther... |
| 12.06.2026 | Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis | SHANGHAI, June 12, 2026 /PRNewswire/ -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the resp... |
| 23.02.2026 | Almirall’s 2025 Results | Almirall, S.A. (ALM):
“2025 was another important year for Almirall as we continue to deliver against our sustained growth trajectory and further expand our leadership in medical dermatology. Another year of double-digit growth of both net ... |
| 27.01.2026 | Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease | Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease.
License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a ... |
| 12.01.2026 | Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis | HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on developing inn... |
| 02.12.2025 | China’s flu season brings a new wave of single-dose antivirals | One morning in mid-November, Shanghai office worker A Liang woke up with a tight throat and a wave of fatigue. By noon, a low fever had set in, a feeling entirely different from the mild cold she had just recovered from days earlier. That w... |
| 14.11.2025 | China’s Leadman Biochem to Buy Majority Stake in Simcere for USD239.5 Million | (Yicai) Nov. 14 -- Leadman Biochemistry, a Chinese maker of in vitro biochemical reagents, said it plans to spend over CNY1.7 billion (USD239.5 million) for a controlling stake in Simcere Sanroad Biological Products, giving it a fast track ... |
| 10.11.2025 | Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage | NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical st... |
| 10.11.2025 | [CIIE] Simcere to Start Producing Swiss Insomnia Drug in China, Building Manufacturing Capabilities for Global Supply | (Yicai) Nov. 10 -- Simcere Pharmaceutical Group showed its redefined cross-border collaboration model at the eighth China International Import Expo, with the Chinese company to soon start manufacturing in China an insomnia drug it licensed ... |
| 31.10.2025 | Financial success for publicly traded biotech companies |
Idorsia is a Basel-based biotech company focused on the discovery, development, and commercialization of transformative medicines – either with in-house capabilities or together with partners. Its lead candidate QUVIVIQ™ (daridorexant) is ... |
| 19.06.2025 | Revolutionizing Cancer Treatment: Simcere Zaiming's Breakthrough in Multiple Myeloma Therapy | In the ever-evolving landscape of oncology, breakthroughs often emerge from the shadows of research labs. Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, is stepping into the spotlight with its innovative therapy for relapsed... |
| 19.06.2025 | Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma | SHANGHAI, June 19, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Phase 1 trial (SIM0500-10... |
| 13.01.2025 | Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma | SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, a... |
| 04.12.2024 | China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke | NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approv... |
| 31.10.2024 | Breakthrough in Stroke Treatment: Sanbexin® Shines at World Stroke Congress | In the world of medicine, breakthroughs often emerge from the shadows of research. The recent World Stroke Congress (WSC) in Nanjing, China, illuminated a significant advancement in stroke treatment. The TASTE-2 study, led by Professor Yong... |
| 30.10.2024 | World Stroke Congress | TASTE-2 significantly reduces stroke disability | NANJING, China, Oct. 30, 2024 /PRNewswire/ -- Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings regarding Sanbexin (edaravone and dexborneol concentrated solution fo... |
| 25.10.2024 | TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability | NANJING, China, Oct. 25, 2024 /PRNewswire/ -- On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Confere... |
| 14.09.2024 | Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration | NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has b... |
| 14.09.2024 | Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration | NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has b... |
| 05.09.2024 | Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration | NANJING, China, Sept. 5, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has be... |
| 30.07.2024 | Is it worth spending RMB 200,000 a year to delay the onset of Alzheimer’s disease? | The loss of control can strike out of the blue, even when preceded by minor symptoms.
When Zhang Li’s mother began experiencing symptoms like dizziness and poor memory, it was initially dismissed as a mild stroke—a minor ailment. However, o... |
| 26.06.2024 | Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA | NANJING, China, June 26, 2024 /PRNewswire/ -- On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetuximab beta injection), a ... |
| 01.06.2024 | Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse | BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by... |
| 01.06.2024 | Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse | BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by... |
| 21.05.2024 | Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024 | NANJING, China, May 21, 2024 /PRNewswire/ -- The 10th European Stroke Organization Congress (ESOC), held in Basel, Switzerland from May 15 to 17, 2024, showcased six studies on Sanbexin® (Edaravone and Dexborneol Concentrated Solution for I... |
| 27.02.2024 | Biopharma firm Simcere Zaiming pockets $134.8m in fresh funding round | Simcere Zaiming Pharmaceutical, a subsidiary of Hong Kong-listed branded generic player Simcere Pharmaceutical Group, has bagged 970 million yuan ($134.8 million) in an equity financing round led by FIIF, a fund managed by CS Capital. |
| 14.03.2023 | Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneo... | NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an innovative oncology pharmaceutical company of ... |
| 09.02.2023 | First Prescription for COSELA® (trilaciclib) Issued in China | - COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital on January 28, 2023
- Simcere delivers drug to patients in 908 days from execution of license agreement to first prescription
NANJING, China... |
| 20.12.2022 | PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT | NANJING, China, Dec. 20, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced today that, XIANNUOXIN (SIM0417), an anti-SARS-CoV-2 drug candidate jointly developed by Simcere with Shanghai Institute of Materia Medica (the &... |
| 16.11.2022 | Simcere and Idorsia enter into a licensing agreement for daridorexant in China | NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd IDIA "Idorsia"), specialized in the discovery, ... |
| 16.11.2022 | Simcere and Idorsia enter into a licensing agreement for daridorexant in China | NANJING, China, Nov. 16, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the disc... |
| 27.10.2022 | Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237 | Second US IND approval this year for the global pharmaceutical group
NANJING, China and BOSTON, Oct. 27, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovative global pharmaceutical company, today announced that the U.S.... |
| 06.10.2022 | Simcere agree license deal of $492M USD with Almirall | Almirall Logo
Simcere Logo
Almirall granted exclusive rights to commercialise SIM0278 for all indications outside the Greater China region, (Mainland China, Hong Kong, Macau and Taiwan)
We are excited to have reached agreement with Almirall... |
| 01.10.2022 | Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc of 492M USD | Simere and Almirall logo
The deal's total amount set a record high, for the out-licensing of preclinical autoimmune assets in China.
Simcere (2096.HK:2096.HK)NANJING, JIANGSU, CHINA, October 1, 2022 /EINPresswire.com/ -- Simcere Pharmaceuti... |
| 29.09.2022 | Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc | Simcere will receive a $15 million upfront payment, and up to $492 million in development and commercial milestone payments considering successful achievements in several indications, with an important part as sales milestones, as well as u... |
| 07.04.2022 | SIMCERE PHARMA (HK.2096) to host 2022 R&D Day | HONG KONG, April 7, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096), an innovation and R&D-driven pharmaceutical company with a mission of "providing today's patients with medicines of the future", will host a virtual R&D Da... |
| 18.03.2022 | Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001 | HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor ... |
| 23.02.2022 | Simcere Pharma (2096.HK) Announces a Positive Profit Alert | HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group"; stock code: 2096.HK), announces a positive profit alert.
Based on a preliminary a... |
| 23.11.2021 | Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments | NANJING, China, Nov. 23, 2021 /PRNewswire/ -- On November 17, 2021, Simcere Pharmaceutical Group Limited (2096.HK) announced that the company has reached collaboration agreement with the Shanghai Institute of Materia Medica (SIMM), Chinese ... |
| 25.03.2021 | Simcere Pharmaceutical : Revised Terms of Reference of the Strategy Committee | Simcere Pharmaceutical Group Limited
ᑊᖹุණྠϞࠢʮ̡
(a company incorporated in Hong Kong with limited liability)
(the "Company")
(Stock code: 2096)
Revised Terms of Reference of the Strategy Committee
(Adopted by the Board on May 13, ... |
| 25.03.2021 | SIMCERE PHARMACEUTICAL GROUP LIMITED
Simcere Pharmaceutical : Revised Terms of Reference of the Strategy Committee | Simcere Pharmaceutical Group Limited
ᑊᖹุණྠϞࠢʮ̡
(a company incorporated in Hong Kong with limited liability)
(the "Company")
(Stock code: 2096)
Revised Terms of Reference of the Strategy Committee
(Adopted by the Board on May 13, ... |
